Piramal Pharma Solutions Boosts HPAPI Capacity with Korsch X3 Tablet Press at Morpeth Site

Event summary

  • Piramal Pharma Solutions installed a Korsch X3 high-containment tablet press at its Morpeth, UK facility, marking the site's 20th anniversary.
  • The X3 press is custom-configured for highly potent active pharmaceutical ingredients (HPAPIs), including Band 5 containment capabilities.
  • The investment expands Morpeth's capacity to manufacture complex, personalized therapies and supports both clinical and commercial-scale production.
  • The press features enhanced safety measures, including glove ports and a misting system to protect staff from airborne contaminants.

The big picture

Piramal Pharma Solutions' investment in the Korsch X3 tablet press aligns with the broader industry trend toward high-containment manufacturing for potent therapies. This strategic move underscores the growing importance of safety and efficiency in pharmaceutical production, particularly as demand for complex and personalized treatments continues to rise. The installation at the Morpeth site, celebrating its 20th anniversary, reinforces Piramal's commitment to innovation and patient-centric manufacturing.

What we're watching

Demand Growth
How the increased capacity will position Piramal to meet rising demand for complex, personalized therapies.
Operational Efficiency
Whether the single-operator concept of the Korsch X3 will enhance productivity and reduce costs.
Market Differentiation
The pace at which Piramal can leverage this investment to strengthen its competitive edge in the CDMO space.